Tuesday, December 24, 2024

 

Evolutionary study reveals the toxic reach of disease-causing bacteria across the Plant Kingdom



John Innes Centre
Toxin 

image: 

Spores of Ceratopteris richardii, the model fern used in the study.

view more 

Credit: Credit Phil Carella



The capacity of bacteria to spread disease across the Plant Kingdom may be much more widespread than previously suspected, according to new analysis. 

John Innes Centre researchers took a comparative evolutionary approach, using the diversity of Pseudomonas syringae bacteria, to determine how this pathogen infects distantly related plants. 

In experiments, researchers in the team of Dr Phil Carella, group leader, analysed the toxin syringomycin produced by the most widely infectious P. syringae strains, and compared its effect on both non-flowering and flowering plants. 

The results showed that syringomycin was toxic in non-flowering plants (represented in this study by model species of a liverwort and fern), causing tissue death and activation of stress-related genes.  

These effects were even more important for infections in non-flowering plants compared to flowering plants, which was surprising as much of our current understanding of how pathogenic (disease causing) bacteria manipulate plant hosts is centered on flowering plants which include some of our major crops. 

By featuring non-flowering species, this study, which appears in Cell Host and Microbe, adds to a growing body of research that shows how bacterial pathogens carry the potential to colonise distantly related plants. 

“Each of the plant species used in this study has a different life history since they last shared a common ancestor 500 million years ago. However, a single group of pathogens can infect each of them using a common set of pathogenicity factors,” said Dr Carella. 

“Our results demonstrate that pathogen virulence may be more general across plants than previously believed,” he added. 

The researchers hypothesise that P.syringae virulence is centered on fundamental processes shared amongst the Plant Kingdom. In this case, the toxin syringomycin likely interferes with cell membranes across each of the diverse plants tested. 

Sometimes non-flowering plants are considered less sophisticated than their flowering relatives which arrived later in evolutionary history, but this study emphasises the importance of analysing the whole of the plant world to understand fundamental mechanisms and processes which could be applied to defending food crops against disease. 

“Overall, our research shows that diverse plants can reveal useful knowledge about plant-pathogen interactions in general, which is informative for research on crop diseases. We don’t eat liverworts, but they can teach us a lot about the core virulence mechanisms of important pathogens,” observes Dr Carella. 

The next step for this research is to explore the role the toxin plays in promoting the spread of bacteria, and how it cooperates with bacterial effector proteins to cause disease. 

Another interesting research question to explore is why some  P.syringae populations do not carry the toxin. 

The group will also expand the diversity of plants used in the experiments to search for those that are resistant to bacterial pathogens. 

A necrotizing toxin enables Pseudomonas syringae infection across evolutionarily divergent plants appears in Cell Host and Microbe. 

 

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility



Patients hospitalized by physicians with higher admission rates likelier to be discharged within 24 hours but no less likely to die than patients hospitalized by physicians with lower admission rate



University of California - Los Angeles Health Sciences




Patients in emergency departments who are treated by physicians with a high propensity to admit those they see into the hospital are more likely to be discharged after only a short stay, suggesting a possible unnecessary admission, while they are no less likely to die, new research suggests.

The findings suggest that differences in physicians’ skill or risk aversion may come into play when they make admitting decisions, said Dr. Dan Ly, assistant professor of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA.

“Physicians, just like professionals in other domains, differ in their abilities and decisions, which has consequences for how much care you might receive, including, in this case, your likelihood of being hospitalized,” said Ly, who co-authored the paper with Stephen Coussens, a health economist and senior data scientist at the Washington state-based data management company Abett. “Some physicians may order more tests and hospitalize more of their patients, but this doesn't appear to translate to better health.”

The findings will be published in the peer-reviewed JAMA Internal Medicine.

While previous studies have shown great variation in emergency department physicians’ likelihood of admitting a patient to the hospital, there has been little evidence whether and how this affects patient outcomes.

Using electronic health records from Veterans Affairs for January 2011 through December 2019, the researchers compared physicians practicing within the same emergency department. Their cross-sectional study captured data for 2,100 physicians in 105 emergency departments across the U.S. comprising more than 2.1 million patient visits. They focused on patients coming into the emergency department for chest pain, shortness of breath, or abdominal pain.

About 41% of the visits led to hospital admission, with 19% of those patients discharged in less than 24 hours. Variation in admission rates varied greatly. For example, patients who saw high-admitting physicians (those in the 90th percentile) were almost twice as likely to be admitted as patients who were treated by low-admitting physicians (those in the 10th percentile), even though their underlying health did not differ. Overall, about 2.5% of patients died within 30 days. The researchers found no relationship between a physician’s admission rate and the 30-day mortality rate of their patients. This lack of relationship was also true for 7-day, 14-day, 90-day, and one-year mortality.

The findings suggest that differences across physicians in admission rates are driven less by a patient’s underlying health than variation in physician decision-making, the researchers write. In addition, these additional hospitalizations from high-admitting physicians led neither to short-term protection from severe outcomes nor to a reduction in patients’ risk for dying for up to a year afterward. And patients who were treated by physicians with a lower propensity to admit spent less total time after their ED visit in the hospital, which suggests that low-propensity physicians were not simply deferring a necessary hospitalization into the future, they write.

Limitations of the study include the possibility that some potential clinical confounders were not captured in the electronic health records; the manner that the researchers used to measure patients’ health prior to the emergency department visit, called the Elixhauser Comorbidity Index score, does not measure the severity of a person’s presenting condition; variations in physician characteristics, such as medical training, could not be controlled for; the findings are specific to the VA, whose patients are largely male, and has emergency department staffing with more non-emergency medicine trained physicians, so the findings may not be applicable to other institutions; and other factors besides the physician also play a role in variation in admission rates.

While more research is needed to fully understand these differences in admission rates, “our study is able to better account for patient differences and make apples-to-apples comparisons between physicians to demonstrate true differences in ED physician practice patterns and show that these differences do not translate to better patient health outcomes,” Ly said.

The study was funded in part by the Veterans Affairs Health Systems Research Center for the Study of Healthcare Innovation Implementation & Policy Locally Initiated Project. (LIP 65-175)

Article: “Variation in Emergency Department Physician Admitting Practices and Subsequent Mortality,” doi: 10.1001/jamainternmed.2024.6925

Patients in emergency departments who are treated by physicians with a high propensity to admit those they see into the hospital are more likely to be discharged after only a short stay, suggesting a possible unnecessary admission, while they are no less likely to die, new research suggests.

The findings suggest that differences in physicians’ skill or risk aversion may come into play when they make admitting decisions, said Dr. Dan Ly, assistant professor of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA.

“Physicians, just like professionals in other domains, differ in their abilities and decisions, which has consequences for how much care you might receive, including, in this case, your likelihood of being hospitalized,” said Ly, who co-authored the paper with Stephen Coussens, a health economist and senior data scientist at the Washington state-based data management company Abett. “Some physicians may order more tests and hospitalize more of their patients, but this doesn't appear to translate to better health.”

The findings will be published in the peer-reviewed JAMA Internal Medicine.

While previous studies have shown great variation in emergency department physicians’ likelihood of admitting a patient to the hospital, there has been little evidence whether and how this affects patient outcomes.

Using electronic health records from Veterans Affairs for January 2011 through December 2019, the researchers compared physicians practicing within the same emergency department. Their cross-sectional study captured data for 2,100 physicians in 105 emergency departments across the U.S. comprising more than 2.1 million patient visits. They focused on patients coming into the emergency department for chest pain, shortness of breath, or abdominal pain.

About 41% of the visits led to hospital admission, with 19% of those patients discharged in less than 24 hours. Variation in admission rates varied greatly. For example, patients who saw high-admitting physicians (those in the 90th percentile) were almost twice as likely to be admitted as patients who were treated by low-admitting physicians (those in the 10th percentile), even though their underlying health did not differ. Overall, about 2.5% of patients died within 30 days. The researchers found no relationship between a physician’s admission rate and the 30-day mortality rate of their patients. This lack of relationship was also true for 7-day, 14-day, 90-day, and one-year mortality.

The findings suggest that differences across physicians in admission rates are driven less by a patient’s underlying health than variation in physician decision-making, the researchers write. In addition, these additional hospitalizations from high-admitting physicians led neither to short-term protection from severe outcomes nor to a reduction in patients’ risk for dying for up to a year afterward. And patients who were treated by physicians with a lower propensity to admit spent less total time after their ED visit in the hospital, which suggests that low-propensity physicians were not simply deferring a necessary hospitalization into the future, they write.

Limitations of the study include the possibility that some potential clinical confounders were not captured in the electronic health records; the manner that the researchers used to measure patients’ health prior to the emergency department visit, called the Elixhauser Comorbidity Index score, does not measure the severity of a person’s presenting condition; variations in physician characteristics, such as medical training, could not be controlled for; the findings are specific to the VA, whose patients are largely male, and has emergency department staffing with more non-emergency medicine trained physicians, so the findings may not be applicable to other institutions; and other factors besides the physician also play a role in variation in admission rates.

While more research is needed to fully understand these differences in admission rates, “our study is able to better account for patient differences and make apples-to-apples comparisons between physicians to demonstrate true differences in ED physician practice patterns and show that these differences do not translate to better patient health outcomes,” Ly said.

The study was funded in part by the Veterans Affairs Health Systems Research Center for the Study of Healthcare Innovation Implementation & Policy Locally Initiated Project. (LIP 65-175)

Article: “Variation in Emergency Department Physician Admitting Practices and Subsequent Mortality,” DOI: 10.1001/jamainternmed.2024.6925

 JAMA NEWS

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity



JAMA Pediatrics





About The Study: 

In this cross-sectional study, U.S. youths ages 0 to 19 years experienced important disparities in firearm and motor vehicle crash fatality rates and increases over time when considering the intersectionality by age group, sex, race, and ethnicity. These findings suggest that a multipronged strategy focused on individual, community, and policy level approaches for specific high-risk groups for each injury mechanism is necessary to address these leading causes of death in U.S. youths.

Corresponding Author: To contact the corresponding author, Lois K. Lee, MD, MPH, email lois.lee@childrens.harvard.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamapediatrics.2024.5089)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.5089?guestAccessKey=fbbec3ca-fec5-4aaa-bfcb-2a3ed1179732&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122324

 


Association of state cannabis legalization with cannabis use disorder and cannabis poisoning



HOW DOES IT COMPARE TO THE STATES PRIOR CASES OF CANNIBIS DISORDER, POISIONONG PRE LEGALIZATION


JAMA Psychiatry\




About The Study:

 In this longitudinal cohort study, medical cannabis laws were associated with increased cannabis use disorder and cannabis poisoning diagnoses, and recreational cannabis laws were associated with increased cannabis poisoning in adults ages 18 to 64 with employer-sponsored health insurance. Communities with increased access to cannabis may experience increased health care use and costs due to increases in cannabis poisoning and cannabis use disorder, and new clinical and policy interventions are needed to curb these rising diagnoses. 

Corresponding Author: To contact the corresponding author, Jayani Jayawardhana, PhD, email jayani.jayawardhana@uky.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(10.1001/jamapsychiatry.2024.4145)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.4145?guestAccessKey=a795f259-4017-4f2e-ab8b-31127f220df5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122324

 

Adoption of “hospital-at-home” programs remains concentrated among larger, urban, not-for-profit and academic hospitals



Study highlights need for targeted incentives to expand program to smaller, rural, and non-teaching hospitals



University of California - Los Angeles Health Sciences



Hospitals that have adopted the Center for Medicare and Medicaid (CMS) “hospital-at-home” program, which serves as an alternative to admission to brick-and-mortar facilities, are concentrated in large, urban, not-for-profit, and academic hospitals, new research suggests.

The findings are among the first to portray the landscape of hospitals participating in this rapidly growing care model, said Dr. Hashem Zikry, a participant in the National Clinician Scholars Program at UCLA and lead author on the paper, which will be published in the peer-reviewed JAMA.

“If CMS’ goal is to continue to expand hospital-at-home, these findings suggest that different incentives or outreach may be needed for smaller, rural, and non-teaching hospitals,” Zikry said.

Established in November 2020, the CMS program allows hospitals to deliver care for acute medical illness to patients in their own homes in lieu of a traditional hospital admission.

 “Imagine, for example, a 70-year-old who needs treatment for pneumonia,” Zikry said. “Instead of being admitted to the brick-and-mortar hospital, hospital-at-home allows this patient to get the same resources, such as antibiotics and vital sign monitoring, in her own home.” An initial motivation for promoting hospital-at-home was to lessen capacity strain on hospitals — a problem that was exposed and exacerbated by the Covid-19 pandemic. “Many hospitals are operating at 100% capacity almost all the time,” said Zikry, “so anything that might free up beds and mitigate that capacity crisis is tremendously appealing to heath systems.”

Initially scheduled to expire in December 2022, Congress extended the hospital-at-home waiver program through the end of 2024 and recently introduced legislation to extend it for another five years. Early participants in the CMS program tended to be large, urban, not-for-profit, academic hospitals. In light of the current proposal to extend the waiver, Zikry and coauthors were curious to see whether participation continued to grow after the initial 2022 extension and whether the characteristics of participating hospitals had changed over time.

The researchers conducted a cross-sectional analysis of short-term acute care hospitals in the United States and used the 2022 American Hospital Association Annual Survey to obtain data on hospital characteristics. They compared hospitals that applied for the waiver between November 2020 and December 2022 (pre-extension hospitals) and those that applied afterward (post-extension). Of about 3,000 hospitals included in the study, 299 obtained the waiver, with 249 of them pre-extension and 50 post-extension.

The study found that adoption of the waiver remained concentrated among large, urban, not-for-profit, and academic hospitals. The characteristics of post-extension hospitals were similar to pre-extension hospitals, although the former were somewhat smaller and demonstrated regional differences.

 Among their findings:

  • Geographically, 49 (98%) post-extension and 226 (91%) pre-extension hospitals were in metropolitan areas
  • Post-extension facilities were most often located in the northeastern (16 hospitals, for 31%) or western U.S (10, for 20%), compared with 30 (12%) and 26 (10%) pre-extension hospitals, respectively. In the south, 19 (38%) were post-extension and 143 (57%) pre-extension
  • Of the post-extension facilities, 24 (48%) had 100 to 299 beds and 20 (40%) had more than 300 beds, compared with 86 (35%) and 126 (51%) pre-extension, respectively
  • Non-profits comprised 46 (92%) post-extension and 201 (81%) pre-extension hospitals
  • Among academic hospitals, 27 (54%) were minor teaching hospitals and 11 (22%) were major teaching hospitals post-extension, compared with 137 (55%) and 64 (26%) pre-extension, respectively.

There are multiple implications of this research, according to Zikry. For one, if CMS wants to expand the reach of hospital-at-home, more work must be done to incorporate smaller, rural, and non-teaching hospitals. The data is clear that these types of hospitals are not seeking to create these programs on their own, potentially because of the resources involved in creating and sustaining their operation until they scale.

Moreover, additional research is needed to understand the practical implications and tradeoffs of hospital-at-home.

“Resources are being poured into these programs around the country,” Zikry said, “yet we still don’t have a comprehensive understanding of how the programs are functioning on the ground.”

Many questions remain, he said.: “Are family members of these patients acting as unpaid caregivers during these admissions? Could these patients do just as well in other care settings? Do patients actually prefer to be at home? And are health systems leveraging this program equitably?”

Study co-authors are Dr. David Schriger of UCLA and Dr. Austin Kilaru of the University of Pennsylvania.

GOOD NEWS

US Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued


9 in 10 Americans say it’s important for parents to have children vaccinated




Annenberg Public Policy Center of the University of Pennsylvania

The public's views of the effectiveness of RSV vaccines 

image: 

Source: Annenberg Public Policy Center's ASAPH surveys, October 2023 and November 2024.

view more 

Credit: Annenberg Public Policy Center




PHILADELPHIA – A year after becoming available, vaccines to protect against RSV in newborns and older adults are being more widely accepted by the American public, according to a new Annenberg Public Policy Center (APPC) health survey conducted in November 2024.

Over half of U.S. adults (52%) think the vaccine given to pregnant individuals to protect their infants from RSV (respiratory syncytial virus) is effective, up from 42% in October 2023, soon after the Centers for Disease Control and Prevention (CDC) recommended the vaccine. And 61% say the RSV vaccine for adults age 60 and older is effective, up from 54% in October 2023.

The rise in perceived effectiveness for the RSV vaccine comes even though there has been no sign to date of a dreaded “tripledemic,” the wave of flu, Covid-19, and RSV illnesses that filled emergency rooms in the fall and winter of 2022-23 and may have resulted in over 100,000 U.S. deaths. As of Dec. 20, 2024, the CDC reports overall moderate levels of acute respiratory illness, though flu season is underway with levels increasing across the country, Covid-19 activity is increasing from low levels in some areas of the country, and RSV activity is high and increasing in most U.S. areas, especially in young children.

The rise also comes as several of president-elect Donald Trump’s nominees for leading policy-making health positions have cast doubt on the efficacy and safety of vaccines, notably Health and Human Services Secretary nominee Robert F. Kennedy Jr., who has said “no vaccine” is safe and effective, and CDC chief nominee Dave Weldon, who, like Kennedy, has promoted the disproven link between vaccines and autism.

The APPC survey findings are based on a nationally representative panel survey of 1,771 U.S. adults fielded from Nov. 14-24, 2024, and has a margin of error of ± 3.3 percentage points. For more on the survey, see the end of this news release or the topline.

Vaccine hesitancy may have plateaued

The past several years have shown evidence of increased vaccine hesitancy. (See our October 2023 survey release, “Vaccine Confidence Falls as Belief in Health Misinformation Grows.”) However, by several measures in the November survey, including the RSV findings noted above, public acceptance of vaccination has risen slightly or held steady:

  • 86% of respondents say the measles, mumps, and rubella vaccine (MMR) is safe, up from 81% in October 2023. The rebound brings it back toward the 88% who perceived it as safe in August 2022.
  • 83% say the flu vaccine is safe, unchanged from October 2023.
  • 65% say the Covid-19 vaccine is safe, unchanged from last fall.
  • The perceived effectiveness of a variety of other vaccines is unchanged from October 2023.
  • Over three-quarters of the public would recommend various vaccines, when appropriate, to members of their families and households.

In addition, despite continuing attacks on the safety and efficacy of certain vaccines by some politicians, 9 in 10 respondents say it is important for parents to get their children vaccinated: 72% say it is very or extremely important and 19% say it is somewhat important. Only 10% say it is not at all or not very important that parents get their children vaccinated.

Flu vaccine vs. Covid-19

In the survey, U.S. adults view the seasonal flu shot as more effective at reducing the risk of getting a severe case of the flu this season (75%) than the Covid booster is at reducing the risk of getting a severe case of Covid this season (55%). There’s been a significant increase in understanding that the flu shot doesn’t necessarily prevent a person who is exposed to the flu from getting sick but it does make the infection less severe (54%, up from 48% in October 2023). Fewer people say they are unsure what effect a flu shot has on a person who is later exposed to someone with the flu (14%, down from 20%).

The November data show that fewer people have received or plan to receive the Covid booster, as compared with the flu shot:

  • Just over half of survey respondents (51%) either got the seasonal flu shot (40%) or say they are very likely to (11%) get it, compared with 38% who either got the latest Covid-19 booster (29%) or say they are very likely to (9%).
  • The most common reason people select to explain why they have received the Covid booster and the flu shot is to protect themselves against catching that illness (82% and 78%, respectively).
  • More people report getting the flu shot because they “get it every year” (76%) than those who report getting the Covid booster because they “get one every time a new booster comes out” (51%).
  • 68% know they can get a Covid booster and a flu shot in the same visit to a health care clinic or pharmacy, unchanged from October 2023, though there’s a significant increase in the number who report that this is definitely true (44%, up from 38% in October 2023).

Flu knowledge

  • Most people (80%) know the effectiveness of the seasonal flu shot varies year to year.
  • Although most people (69%) see this year’s flu vaccine as effective at reducing the risk of getting the flu (unchanged from October 2023), more people think it is ineffective this fall (20%) than last fall (15%).
    • In fact, early reports suggest that this seasonal flu vaccine may be less effective than last year’s: Based on reports from five South American countries, the CDC has said the effectiveness of the seasonal flu vaccine at cutting the risk of hospitalization among high-risk groups appears to be 35%, lower than the 51.9% seen in those countries last flu season, according to WebMD.
  • 69% know that there is value in getting a flu shot after November, but 19% are unsure.
  • Most people (80%) know it is possible to spread the flu to others even if you have no symptoms, up from 76% in January of 2023. (The CDC says that some “people can be infected with influenza viruses and have no symptoms but may still be able to spread the virus to their close contacts.”)
  • Most (71%) know that the flu shot is the best defense against seasonal flu.
  • However, only 42% believe that everyone 6 months of age and older should get a flu shot, unchanged from last year.

The public's view of the effectiveness of various vaccines 

Beliefs in vaccine effectiveness and safety

Longstanding vaccines such as the MMR, polio, and Tdap (tetanus, diphtheria, and pertussis) vaccines are usually top-rated by the public in effectiveness, safety, and in recommendations that others get the vaccines. Newer vaccines such as the Covid-19 vaccine or those for which public health advice has recently changed – such as the CDC recommendation that adults 50 and older get a vaccine against pneumonia – are less familiar and often lower-rated by the public.

Recommending vaccines. Here are the public’s views on recommending vaccines to others:

  • MMR vaccine: 90% would be likely to recommend an MMR vaccine for a child in their household who is either between the ages of 12-15 months or 4 to 6 years old.
  • Polio vaccine: 88% would be likely to recommend a polio vaccine to a child in their household of 2 to 6 months old.
  • Tdap vaccine: 85% would be likely to recommend a Tdap vaccine to a child in their household of 11-12 years old or an adult in their family.
  • Shingles vaccine: 82% would be likely to recommend a shingles vaccine to someone age 50+ in their family.
  • HPV vaccine: 79% would be likely to recommend an HPV (human papillomavirus) vaccine for a child aged 11 or 12 years old in their household.
  • Pneumonia vaccine: 77% would be likely to recommend a pneumonia vaccine to a person aged 50 or older in their family, down from 84% who were likely to recommend it to someone 65 or older in their family in April 2022. The CDC recommended lowering the age for the vaccine on Oct. 23, 2024, weeks before this survey was fielded.

Vaccine safety. Public views on vaccine safety:

  • MMR: 86% say the MMR vaccine is safe, up from 81% in October 2023 (as noted above)
  • Flu: 83% say the flu vaccine is safe, unchanged
  • Covid-19: 65% say the Covid-19 vaccine is safe, unchanged from October 2023 but lower than 73% in August 2022.

Vaccine effectiveness. Public views on vaccine effectiveness are stable with the exception of RSV, which rose as noted above. The following percentages saw these vaccines as effective. Comparisons are to October 2023, if this question was asked then:

  • MMR: 86% see the vaccine as effective (unchanged)
  • Polio: 85%
  • Tdap: 80%
  • Flu: 75% (unchanged)
  • Shingles: 74% (unchanged)
  • Pneumonia: 71% (unchanged)
  • HPV: 65% (unchanged)
  • Covid-19: 65% (unchanged)
  • RSV for adults 60 and older: 61%, up from 54% in October 2023
  • RSV for pregnant individuals: 52%, up from 42% in October 2023

APPC’s Annenberg Science and Public Health knowledge survey

The survey data come from the 22nd wave of a nationally representative panel of 1,771 U.S. adults conducted for the Annenberg Public Policy Center by SSRS, an independent market research company. Most have been empaneled since April 2021. To account for attrition, small replenishment samples have been added over time using a random probability sampling design. The most recent replenishment, in September 2024, added 360 respondents to the sample. This wave of the Annenberg Science and Public Health Knowledge (ASAPH) survey was fielded Nov. 14-24, 2024. The margin of sampling error (MOE) is ± 3.3 percentage points at the 95% confidence level. All figures are rounded to the nearest whole number and may not add to 100%. Combined subcategories may not add to totals in the topline and text due to rounding.

Download the topline and the methods report.

The policy center has been tracking the American public’s knowledge, beliefs, and behaviors regarding vaccination, Covid-19, flu, RSV, and other consequential health issues through this survey panel over the past two-and-a-half years. In addition to APPC director Kathleen Hall Jamieson, APPC’s team on the survey includes research analysts Laura A. Gibson and Shawn Patterson Jr.; Patrick E. Jamieson, director of the Annenberg Health and Risk Communication Institute; and Ken Winneg, managing director of survey research.

###

The Annenberg Public Policy Center was established in 1993 to educate the public and policy makers about communication’s role in advancing public understanding of political, science, and health issues at the local, state, and federal levels.

 

Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label




Distinguished professor Inga Neumann discusses groundbreaking social behavior research in exclusive Genomic Press Interview



Genomic Press

Inga D. Neumann working at the Tacugama Chimpanzee Sanctuary in Sierra Leone 

image: 

Inga D. Neumann working at the Tacugama Chimpanzee Sanctuary in Sierra Leone, preparing enrichment material for chimpanzee orphans.

view more 

Credit: Inga D. Neumann




REGENSBURG, Bavaria, Germany, 24 December 2024 – In a comprehensive Genomic Press Interview, Professor Inga Neumann, Chair of the Department of Behavioural and Molecular Neurobiology at the University of Regensburg, reveals groundbreaking insights into how oxytocin shapes social behavior and emotional responses in the brain.

The interview, published in Brain Medicine (DOI: 10.61373/bm024k.0139), showcases Professor Neumann's pioneering research on neuropeptides, particularly oxytocin, which has evolved far beyond its popular characterization as simply the "love hormone."

"I am convinced that increasing our knowledge about the stimuli, dynamics, and consequences of their intracerebral release at the behavioural, physiological, cellular, and molecular levels will improve our understanding of general brain mechanisms," explains Professor Neumann, whose work spans from molecular mechanisms to behavioral outcomes.

Her research team has developed innovative approaches to studying social anxiety, including a breakthrough mouse model of social fear conditioning. This work has opened new avenues for understanding how chronic stress and early life experiences influence social behavior patterns.

"We started to focus on the potential role of the brain's oxytocin and AVP systems as therapeutic targets for psychiatric diseases such as depression and anxiety disorders or autism," Professor Neumann notes, highlighting the clinical implications of her research. "The hope is that one day it will be possible to apply oxytocin reliably to treat – for example – treatment-resistant patients suffering from anxiety disorders, especially social anxiety, but also autism and schizophrenia."

As the first woman appointed full professor at the Faculty of Biology and Preclinical Medicine at the University of Regensburg, Professor Neumann has not only advanced scientific understanding but also broken gender barriers in academia. Her leadership extends to directing the Elite Masters Programme in Experimental and Clinical Neuroscience and heading the Graduate School "Neurobiology of Socio-Emotional Dysfunctions."

The interview provides unique insights into the challenges and triumphs of conducting neuroscience research across different political eras, from her early work in East Germany to her current position as a leading international researcher. "My beginnings as a scientist behind the 'Iron Curtain' were bumpy," she recalls, describing how her team had to build their own research equipment using donated materials.

Her current research focuses on understanding the molecular mechanisms of social fear, particularly investigating the role of oxytocin, CRF, and other neuroactive molecules. This work has significant implications for treating social anxiety disorders and understanding stress resilience.

Looking ahead, Professor Neumann's research raises intriguing questions about the future of psychiatric treatment: How can we optimize the delivery of oxytocin-based therapies to the brain? What role might epigenetic factors play in social behavior disorders? How can we better translate findings from animal models to human therapeutic applications?

Professor Inga Neumann's Genomic Press interview is part of a larger series that highlights the people behind today’s most influential scientific ideas. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that explores the scientist’s impact on the field, while also touching on broader human themes. More information on the research leaders and research rising stars featured by Genomic Press can be found in our publication website: https://genomicpress.kglmeridian.com/.

The complete interview, titled "Inga D. Neumann: Molecular underpinnings of the brain oxytocin system and its involvement in socio-emotional behaviour: More than a love story," is available on 24 December 2024 in Brain Medicine. The article is freely accessible online at https://doi.org/10.61373/bm024k.0139.

About Brain MedicineBrain Medicine (ISSN: 2997-2639) is a peer-reviewed medical research journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal’s scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.